Blockchain Registration Transaction Record

VERAXA Biotech and OmniAb Advance Targeted Cancer Therapy

VERAXA Biotech (VRXA) and OmniAb (OABI) advance VXA-222 bispecific ADC program targeting solid tumors with precision AND-gate approach. Key milestone achieved in collaboration.

This news matters because it represents progress in developing more precise cancer treatments. VXA-222 uses an 'AND-gate' mechanism that may reduce side effects by only activating in the presence of two specific tumor antigens, potentially improving outcomes for patients with solid tumors. The collaboration between VERAXA and OmniAb accelerates the development of next-generation antibody-drug conjugates, which could offer new hope for difficult-to-treat cancers. For investors, the milestone signals that the partnership is delivering on its goals, potentially increasing the value of VERAXA's pipeline and its stock (VRXA).